Smith & Nephew (SN) Trading 0% Higher
Smith & Nephew plc (LON:SN) shares traded up 0% on Friday . The stock traded as high as GBX 1,294 ($17.42) and last traded at GBX 1,293 ($17.40). 1,128,212 shares were traded during mid-day trading, a decline of 57% from the average session volume of 2,610,000 shares. The stock had previously closed at GBX 1,293 ($17.40).
A number of analysts have recently commented on SN shares. Berenberg Bank restated a “hold” rating and set a GBX 1,340 ($18.03) price objective on shares of Smith & Nephew in a report on Friday, November 3rd. Jefferies Group restated a “buy” rating and set a GBX 1,515 ($20.39) price objective on shares of Smith & Nephew in a report on Monday, November 6th. Citigroup restated a “sell” rating and set a GBX 1,160 ($15.61) price objective on shares of Smith & Nephew in a report on Thursday, October 12th. J P Morgan Chase & Co restated a “neutral” rating and set a GBX 1,361 ($18.32) price objective on shares of Smith & Nephew in a report on Tuesday, October 10th. Finally, Goldman Sachs Group restated a “neutral” rating and set a GBX 1,380 ($18.57) price objective on shares of Smith & Nephew in a report on Monday, September 11th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and two have given a buy rating to the company. Smith & Nephew presently has an average rating of “Hold” and a consensus price target of GBX 1,315.82 ($17.71).
Smith & Nephew Company Profile
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.
Receive News & Stock Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related stocks with our FREE daily email newsletter.